- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01216371
Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) (SMAT)
February 10, 2012 updated by: Heidrun Rexer, Association of Urologic Oncology (AUO)
Prospektiv Randomisierte Multizentrische Phase II-Studie Zur Metastasenresektion Von Lungenfiliae (Poor-prognosis) Beim Klarzelligen Nierenzellkarzinom +/- Adjuvante Sunitinibtherapie über 1 Jahr SMAT - AN 20/04 Der AUO
The aim ist to identify biomarkers in the blood, to indicate early response or early treatment resistance.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Prospective randomized multi-center Phase II trial for resection of metastases from pulmonary metastases (poor prognosis) in clear cell renal cell carcinoma + / - adjuvant sunitinib therapy over one year
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Susanne Krege, Priv. Doz. Dr. med.
- Phone Number: 02 151 / 334-23 81
Study Locations
-
-
-
Berlin, Germany, 10117
- Not yet recruiting
- Universitätsmedizin Charité Berlin
-
Contact:
- Steffen Weikert, Priv. Doz. Dr. med.
- Phone Number: 030/84 45-40 84
-
Principal Investigator:
- Steffen Weikert, Priv. Doz. Dr. med.
-
Sub-Investigator:
- Kempkensteffen Carsten, Dr. med.
-
Sub-Investigator:
- Jonas Busch, Dr. med.
-
Sub-Investigator:
- Jan Gregor, Dr. med.
-
Sub-Investigator:
- Jens Neudecker, Dr. med.
-
Sub-Investigator:
- Jens C. Rückert, Dr. med.
-
Sub-Investigator:
- Gertrud Feldmann
-
Berlin, Germany, 10787
- Not yet recruiting
- Franziskus Krankenhaus
-
Contact:
- Jörg Neymeyer, Dr. med.
- Phone Number: 030/26 38-38 01
-
Principal Investigator:
- Jörg Neymeyer, Dr. med.
-
Sub-Investigator:
- Thomas Wülfing, Dr. med.
-
Berlin, Germany, 14165
- Not yet recruiting
- Helios Klinikum Emil Von Behring
-
Contact:
- Kollmeier Jens, Dr. med.
- Phone Number: 030/81 02-14 47
-
Sub-Investigator:
- Jens Kollmeier, Dr. med.
-
Sub-Investigator:
- Bettina Schlolaut, Dr. med.
-
Düsseldorf, Germany, 40255
- Recruiting
- University Hospital of Düsseldorf
-
Contact:
- Peter Albers, Prof. Dr. med.
- Phone Number: 0211/811-81 10
-
Principal Investigator:
- Peter Albers, Prof. Dr. med.
-
Sub-Investigator:
- Jasper Decoene
-
Sub-Investigator:
- Zenginli Hakan
-
Sub-Investigator:
- Claus F. Eisenberger, Prof. Dr. med.
-
Sub-Investigator:
- Wolfram T. Knoefel, Prof. Dr. med.
-
Sub-Investigator:
- Almut Diem
-
Essen, Germany, 45122
- Recruiting
- University Hospital of Essen
-
Contact:
- Herbert Rübben, Prof. Dr. med.
- Phone Number: 0201/723-32 10
-
Principal Investigator:
- Herbert Rübben, Prof. Dr. med.
-
Sub-Investigator:
- Marcus Schenk, Dr. med.
-
Sub-Investigator:
- Farnk vom Dorp, Dr. med.
-
Sub-Investigator:
- Min Ju, Dr. med.
-
Sub-Investigator:
- Stephan Tschirdewahn
-
Sub-Investigator:
- Michaela Löbert
-
Essen, Germany, 45239
- Not yet recruiting
- Ruhrlandklinik Department of Thoracic Surgery
-
Contact:
- Christiane Zimmermann
- Phone Number: 0201/433-43 24
-
Sub-Investigator:
- Georgios Stamatis, Prof. Dr. med.
-
Sub-Investigator:
- Stefan Welter, Dr. med.
-
Sub-Investigator:
- Silvia Fechner, Dipl. med.
-
Freiburg, Germany, 79106
- Recruiting
- University Hospital of Freiburg
-
Contact:
- Ulrich Wetterauer, Prof. Dr. med.
- Phone Number: 0761/270-2891
-
Principal Investigator:
- Ulrich Wetterauer, Prof. Dr. med.
-
Sub-Investigator:
- Christian Leiber, Dr. med.
-
Sub-Investigator:
- Christian Stremmel, Prof. Dr. med.
-
Sub-Investigator:
- Jutta Günter, Dr. med.
-
Heidelberg, Germany, 69119
- Recruiting
- University Hospital of Heidelberg
-
Contact:
- Markus Hohenfellner, Prof. Dr. med.
- Phone Number: 06221/56-63 21
-
Principal Investigator:
- Markus Hohenfellner, Prof. Dr. med.
-
Sub-Investigator:
- Pahernick Sascha, Priv. Doz. Dr. med.
-
Sub-Investigator:
- Gencay Hatiboglu, Dr. med.
-
Sub-Investigator:
- Johannes Huber, Dr. Dr. med.
-
Sub-Investigator:
- Joachim Pfannschmidt, Priv. Doz. Dr. med.
-
Sub-Investigator:
- Hendrik Dienemann, Prof. Dr. med.
-
Krefeld, Germany, 47805
- Recruiting
- urological hospital of Maria Hilf Krankenhaus Krefeld
-
Contact:
- Susanne Krege, Priv. Doz. Dr. med.
- Phone Number: 02151/334-52 74
-
Principal Investigator:
- Susanne Krege, Priv. Doz. Dr. med.
-
Sub-Investigator:
- Florian Hartmann, Dr. med.
-
München, Germany, 81377
- Not yet recruiting
- Hospital of Großhadern
-
Contact:
- Michael Staehler, Dr. med.
- Phone Number: 089/70 95-0
-
Principal Investigator:
- Michael Staehler, Dr. med.
-
Sub-Investigator:
- Cordula Nordhaus, Dr. med.
-
Sub-Investigator:
- Philipp Nuhn, Dr. med.
-
Sub-Investigator:
- Hauke Winter, Priv. Doz. Dr. med.
-
Sub-Investigator:
- Rudolf Hatz, Prof. Dr. med.
-
Sub-Investigator:
- Sylvia Dondl
-
Wiesbaden, Germany, 65199
- Recruiting
- Dr.-Horst-Schmidt-Kliniken GmbH
-
Contact:
- Norbert Frickhofen, Prof. Dr. med.
- Phone Number: 0611/43-30 09
-
Principal Investigator:
- Norbert Frickhofen, Prof. Dr. med.
-
Sub-Investigator:
- Bernd Jung, Dr. med.
-
Sub-Investigator:
- Heinz G. Fuhr, Dr. med.
-
Sub-Investigator:
- Joachim Schirren, Prof. Dr. med.
-
Sub-Investigator:
- Servet Bölükbas, Dr. med.
-
Sub-Investigator:
- Sabine Labenz
-
Sub-Investigator:
- Birgit Wilde
-
Sub-Investigator:
- Klaudia Fischbach
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- >/= 2 synchronous or within 24 Months after Nephrectomy occured pulmonary metastases. Patients in whom more back than 2 years of a solitary lung metastasis, bone metastasis or brain metastasis was resected, may also be included in the study.
- Aged 18 to 75 years
- functionally acceptable surgical risk
- Women in conceptional age: negative pregnancy test and adequate contraception
- Adequate hematologic, renal, hepatic and coagulation-physiological functions
- Amylase/ Lipase < 1,5 x upper limit of normal
- Informing the patient about the study and the present written consent to participate after clarification in accordance with the stipulations of AMG(german drug law), and the principles of GCP ("informed consent")
- Patient compliance and geographic proximity to allow adequate follow-up
Exclusion Criteria:
- Presence of other metastases outside the lung
- progress in the 12-week sunitinib therapy before resection of metastases
- R1 or R2-finding in resection of metastases
- Dialysis after nephrectomy
- Previous or existing serious cardiovascular (grade III - IV according to NYHA(New York Heart Association)) disease, active angina pectoris or ischemia, myocardial infarction within previous 6 months , uncontrolled hypertension(RR diastolic 120 mmHg(Millimeters of mercury))
- serious hematopoetic (e.g. serious Bone marrow aplasia), pulmonary, hepatic or renal Disease
- Stroke within the previous six months
- Patients with poorly controlled diabetes mellitus
- Serious bacterial or fungal infections
- chronic hepatitis B or C, HIV(human immunodeficiency virus) infection
- autoimmune disease
- prior organ transplantation
- prior autologous bone marrow transplant or stem cell transferred within the last 4 months before study
- Neuropsychiatric diseases that affect patient compliance
- Manifesto, second malignancy or other malignancy within the past 5 years (except basal cell carcinoma, carcinoma in situ of the cervix, incidental prostate carcinoma, superficial urothelial Ca pTaG1-2 and pT1G1)
- Therapy with immunotherapeutic agents including monoclonal antibodies, cytotoxic drugs or hormones (other than bisphosphonates and oral contraceptives) within the last 4 weeks prior to enrollment. Previous use of inhibitors of Ras/Raf-, MEK kinase, AKT kinase and mTOR inhibitors or induction of Farnesyltransferase
- Previous use of angiogenesis inhibitors such as VEGF / VEGFR, PDGF / PDGFR and other key molecules of angiogenesis
- parallel treatment with rifampicin
- Participation in other treatment studies in the last 4 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sunitinib
one year adjuvant treatment with sunitinib
|
one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break
Other Names:
|
Placebo Comparator: Placebo
one year treatment with placebo
|
one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
2 year relapse-free survival
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
perioperative mortality and morbidity
Time Frame: 5 years
|
5 years
|
Side effect of adjuvant therapy
Time Frame: 5 years
|
5 years
|
Quality of Life of the Patient
Time Frame: 5 years
|
5 years
|
Overall Survival
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Susanne Krege, Priv. Doz. Dr. med., urological hospital of Maria Hilf Krankenhaus Krefeld
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (Anticipated)
October 1, 2015
Study Completion (Anticipated)
October 1, 2015
Study Registration Dates
First Submitted
October 6, 2010
First Submitted That Met QC Criteria
October 6, 2010
First Posted (Estimate)
October 7, 2010
Study Record Updates
Last Update Posted (Estimate)
February 13, 2012
Last Update Submitted That Met QC Criteria
February 10, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Kidney Neoplasms
- Neoplastic Processes
- Carcinoma, Renal Cell
- Lung Neoplasms
- Carcinoma
- Neoplasm Metastasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Sunitinib
Other Study ID Numbers
- AN 20/04
- 2008-007609-36 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingUnresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell CarcinomaUnited States, Canada
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
Clinical Trials on Sunitinib
-
AGO Study GroupPhilipps University Marburg Medical Center; HSK Reasearch GmbH WiesbadenCompletedPlatinum Refractory Epithelial Ovarian Cancer | Primary Cancer of the Peritoneum | Cancer of the Fallopian TubeGermany
-
Mothaffar RimawiTerminated
-
Cogent Biosciences, Inc.RecruitingMetastatic Cancer | Advanced Gastrointestinal Stromal TumorsUnited States, Korea, Republic of, Spain, United Kingdom, Australia, France, Italy, Netherlands, Taiwan, Germany, Denmark, Hong Kong, Canada, Sweden, Norway, Mexico, Czechia, Argentina, Hungary, Brazil, Chile, Poland
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
PfizerCompletedBreast NeoplasmsUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
PfizerCompletedGastrointestinal Stromal TumorsKorea, Republic of
-
California Pacific Medical Center Research InstitutePfizer; University of California, San FranciscoCompleted
-
PfizerCompletedGastrointestinal Stromal TumorsUnited States, Czechia, France
-
Asan Medical CenterCompletedMetastatic Renal Cell CarcinomaKorea, Republic of